STOCK TITAN

Ventyx Biosciences, Inc. - $VTYX STOCK NEWS

Welcome to our dedicated page for Ventyx Biosciences news (Ticker: $VTYX), a resource for investors and traders seeking the latest updates and insights on Ventyx Biosciences stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ventyx Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ventyx Biosciences's position in the market.

Rhea-AI Summary
Ventyx Biosciences, Inc. (Nasdaq: VTYX) announced financial results for Q3 2023, with $300.8 million in cash, and provided updates on their clinical-stage portfolio. The updates include Phase 2 data for VTX002 in ulcerative colitis, an interim efficacy analysis for VTX958 in Crohn’s disease, and updates on Phase 2 trials for VTX2735 and VTX3232. Financially, R&D expenses were $49.8 million, G&A expenses were $8.2 million, and net loss was $54.0 million for the quarter ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.17%
Tags
-
Rhea-AI Summary
Ventyx Biosciences announces Phase 2 trial results for VTX958 in plaque psoriasis, achieving statistical significance on primary and secondary endpoints. However, efficacy did not meet internal target, leading to termination of further development in psoriasis and psoriatic arthritis. Ongoing Phase 2 trial in Crohn's disease will continue. Cash balance of $300.8M as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-80.62%
Tags
-
Rhea-AI Summary
Ventyx Biosciences announces positive results from Phase 2 trial of VTX002 for ulcerative colitis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.93%
Tags
Rhea-AI Summary
Ventyx Biosciences executives to participate in investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
conferences
-
Rhea-AI Summary
Ventyx Biosciences, Inc. (Nasdaq: VTYX) completed enrollment in Phase 2 trials of VTX002 (S1P1R modulator) in ulcerative colitis and VTX958 (TYK2 inhibitor) in plaque psoriasis. The company has $332.3 million in cash and marketable securities, expected to fund operations into 2025. Ventyx to host a conference call and webcast today at 4:30PM ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.22%
Tags
-
Rhea-AI Summary
Ventyx Biosciences, Inc. will report financial results for Q2 2023 on August 10, 2023. The company will host a conference call and webcast to discuss the financial results and recent progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
conferences earnings
Rhea-AI Summary
Ventyx Biosciences, Inc. (Nasdaq: VTYX) announced that its executives will participate in a fireside chat at the Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023. The company focuses on advancing novel oral therapies for inflammatory diseases with unmet medical needs. The webcast of the presentation will be available on the Ventyx website, with a replay available for thirty days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.36%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
conferences
Ventyx Biosciences, Inc.

Nasdaq:VTYX

VTYX Rankings

VTYX Stock Data

313.02M
40.61M
3.2%
89.51%
13.09%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO

About VTYX

we are a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high value targets. ventyx now includes combined assets from three separate companies: oppilan pharma, targeting s1p1r, zomagen biosciences, targeting nlrp3 and the inflammasome, and ventyx biosciences, targeting tyk2.